Associations of Serum Urate and Cardiovascular Events in a Clinical Trial of Interleukin-1β Blockade.

ABSTRACT:

Background

Serum urate (SU) associates with cardiovascular (CV) events, mortality, and gout.

Objectives

The purpose of this study was to assess whether SU predicts CV risk in a trial of interleukin (IL)-1β inhibition with canakinumab, and whether IL-1β blockade, kidney function, or gout alter these associations.

Methods

This study is a subanalysis of the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS), which randomized 10,061 patients with prior myocardial infarction and elevated high-sensitivity C-reactive protein to 3 doses of canakinumab or placebo. SU was measured at baseline. Cox proportional hazards models compared major adverse cardiovascular events (MACE), CV death, and all-cause mortality among those with SU ≤6.8 mg/dL (normal), 6.8 to 9.0 mg/d

SUBMITTER: Adamstein NH 

PROVIDER: S-EPMC11803220 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature